Get the Stockscreener App
3.65
2.14%
-0.08
Acumen Pharmaceuticals Inc stock is currently priced at $3.65, with a 24-hour trading volume of 78,024.
It has seen a -2.14% decreased in the last 24 hours and a +5.19% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $3.77 pivot point. If it approaches the $3.64 support level, significant changes may occur.
Previous Close:
$3.73
Open:
$3.74
24h Volume:
78,024
Market Cap:
$219.29M
Revenue:
-
Net Income/Loss:
$-52.37M
P/E Ratio:
-3.2018
EPS:
-1.14
Net Cash Flow:
$-43.09M
1W Performance:
+8.63%
1M Performance:
+5.19%
6M Performance:
+60.09%
1Y Performance:
-33.03%
1D Range:
$3.56
$3.7669
52W Range:
$1.8101
$11.31
Acumen Pharmaceuticals Inc Stock (ABOS) Company Profile
Name
Acumen Pharmaceuticals Inc
Sector
Industry
Phone
434 297 1000
Address
427 Park St., Charlottesville
Acumen Pharmaceuticals Inc Stock (ABOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-20-23 | Resumed | BofA Securities | Buy |
| May-18-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-15-22 | Initiated | BTIG Research | Buy |
| Jun-30-22 | Initiated | H.C. Wainwright | Buy |
| Jan-21-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-26-21 | Initiated | BofA Securities | Neutral |
| Jul-26-21 | Initiated | Credit Suisse | Outperform |
| Jul-26-21 | Initiated | Stifel | Buy |
| Jul-26-21 | Initiated | UBS | Buy |
View All
Acumen Pharmaceuticals Inc Stock (ABOS) Latest News
Acumen Pharmaceuticals, Inc. Forecasted to Post Q2 2024 Earnings of ($0.25) Per Share (NASDAQ:ABOS) - Defense World
Defense World
Q2 2024 EPS Estimates for Acumen Pharmaceuticals, Inc. Increased by Analyst (NASDAQ:ABOS) - MarketBeat
MarketBeat
HC Wainwright Reiterates “Buy” Rating for Acumen Pharmaceuticals (NASDAQ:ABOS) - Defense World
Defense World
Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights - br.ADVFN.com
br.ADVFN.com
Acumen Pharmaceuticals (NASDAQ:ABOS) Stock Rating Reaffirmed by HC Wainwright - MarketBeat
MarketBeat
Acumen Pharmaceuticals' (ABOS) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
MarketBeat
Acumen Pharmaceuticals Inc Stock (ABOS) Financials Data
Acumen Pharmaceuticals Inc (ABOS) Net Income 2024
ABOS net income (TTM) was -$52.37 million for the quarter ending December 31, 2023, a -22.20% decrease year-over-year.
Acumen Pharmaceuticals Inc (ABOS) Cash Flow 2024
ABOS recorded a free cash flow (TTM) of -$43.09 million for the quarter ending December 31, 2023, a -22.01% decrease year-over-year.
Acumen Pharmaceuticals Inc (ABOS) Earnings per Share 2024
ABOS earnings per share (TTM) was -$1.09 for the quarter ending December 31, 2023, a -2.83% decline year-over-year.
Acumen Pharmaceuticals Inc Stock (ABOS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Meisner Derek M | Chief Legal Officer & Corp Sec |
Jan 19 '24 |
Sale |
3.48 |
8,933 |
31,048 |
108,867 |
| Zuga Matt | CFO & Chief Business Officer |
Jan 18 '24 |
Sale |
3.71 |
4,242 |
15,717 |
211,445 |
| Siemers Eric | Chief Medical Officer |
Jan 18 '24 |
Sale |
3.71 |
3,124 |
11,604 |
117,576 |
| Barton Russell | Chief Operating Officer |
Jan 18 '24 |
Sale |
3.73 |
2,833 |
10,555 |
96,867 |
| Ives Jeffrey L. | Director |
Aug 17 '23 |
Option Exercise |
0.75 |
41,949 |
31,519 |
39,149 |
| Ives Jeffrey L. | Director |
Aug 17 '23 |
Sale |
6.49 |
41,949 |
272,334 |
0 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Jul 21 '23 |
Buy |
7.75 |
5,161,290 |
39,999,998 |
13,043,179 |
About Acumen Pharmaceuticals Inc
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapeutics for the treatment of Alzheimer's and other neurodegenerative diseases. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, which is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is based in Charlottesville, Virginia.
0.77%
1.20%
Cap:
|
Volume (24h):